Deborah Pulliam, APRN
Family · Springfield, ILNPI 1083261218
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $409 and has fallen 91.2% since, to $36 in 2024.
Across 31 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$88
- Merck$60
- AstraZeneca$60
- Stryker$58
- Sanofi-aventis U.S. LLC$43
- Amgen$39
- plus $168 from 8 others
What the payments were for
- Food & beverage$516100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 5 | $88 |
| Merck | 4 | $60 |
| AstraZeneca | 4 | $60 |
| Stryker | 1 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Amgen | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Orthofix Medical, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Johnson & Johnson | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| GSK | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Mylan Specialty L.p. | 1 | $11 |
How this compares
$516 in reported general payments places this provider in the 60th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 38 | $129 |
| Gabapentin | 24 | $115 |
| Ondansetron Hcl | 30 | $69 |
| Meloxicam | 29 | $63 |
| Tizanidine Hcl | 33 | $44 |
Paid to pharmacies, not to this prescriber.
Other family in Springfield
- Jenna PelcSpringfield$53K
- Aubrie HubbertSpringfield$18K
- Ruth CarricoChicago$578K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.